Skip to main content
Funded Studies

Almira (Ellie) Chabi, MD

Chief Medical Officer and Chief Developmental Officer at HanAll Pharmaceutical International Inc.

Location: Rockville, MD United States

Dr. Almira (Ellie) Chabi, is a physician-scientist with deep experience as an executive and board member, who is serving as Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International. Dr. Chabi leads programs across multiple therapeutic areas including neurology, immunology, oncology, and ophthalmology as well as applications of artificial intelligence. She is also serving on the Scientific and Medical Research Funding Grants Working Group at the California Institute for Regenerative Medicine.

Dr. Chabi previously held the position of Vice President and Global Therapeutic Area Head for Glaucoma & Neuroprotection as well as Lead for Artificial Intelligence Programs at Santen. Prior to Santen, she worked at Genentech including a senior role on a pivotal Phase III program encompassing over 20 countries. Dr. Chabi began her pharmaceutical career at Merck in the Neuroscience & Ophthalmology Clinical Research Group, working on a range of projects within Ophthalmology as well as Neuroscience leading to multiple successful NDA filings.  

In addition to expertise in drug discovery and development, as well as biomarker and device development, she has been extensively involved in due diligences for business development and venture capital teams. Dr. Chabi is also an alumna of Wharton Business School’s Executive Management Program and has served as a board representative in multiple companies.

Associated Grants

  • Development of a Nurr1 Activator as a Novel Therapeutic for Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.